echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shanghai Pharmaceutical Holding Subsidiary Rivaroxaban Tablets Approved for Production

    Shanghai Pharmaceutical Holding Subsidiary Rivaroxaban Tablets Approved for Production

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 8, Shanghai Pharmaceuticals issued an announcement stating that the rivaroxaban tablets of its subsidiary, Changzhou Pharmaceutical Factory, received the "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production


    Rivaroxaban is a new type of oral anticoagulant.


    Clinically, Rivaroxaban is widely used in the prevention and treatment of venous thromboembolic diseases and stroke prevention in non-valvular atrial fibrillation.


    As of the date of this announcement, the main manufacturers of the drug in China include Qilu Pharmaceutical Co.


    The IQVIA database shows that the purchase amount of the drug hospital in 2020 will be RMB 2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.